Reyon Pharmaceutical Co., Ltd. (102460.KS) Stock

102460.KS logo

Reyon Pharmaceutical Co., Ltd.

102460.KSSouth Korea
Healthcare

Company profile

Reyon Pharmaceutical reported revenue of 145.93 billion KRW for fiscal year 2025, down 1.6% from fiscal year 2024. In Q1 2026 (the quarter ended March 31, 2026) revenue was 36.05 billion KRW, down 1.9% from a year before. Republic of Korea was its largest region in fiscal year 2024, with 99% of revenue. In Q1 2026 it reported a net loss of 10.74 billion KRW, against net income of 216.09 million KRW a year earlier. Our analysis of its filings shows revenue shrinking from 151.07 billion KRW in fiscal year 2023 to 145.93 billion KRW in fiscal year 2025, 1.7% a year on average. Reyon Pharmaceutical reports about 461 full-time employees.

What stands out

  • It reported a net loss of 29.63 billion KRW in fiscal year 2025, after a profit of 4.15 billion KRW in fiscal year 2024.
  • Its net profit margin over the last four reported quarters was -23.9%, against a median of 0.9% for 6 listed companies of similar size in its industry.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Reyon Pharmaceutical Co., Ltd.

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. It also develops VM202RY, a vascular neurological disease, etc. gene therapy drug, which is in Phase II clinical trial to treat coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral sclerosis; VM206RY, anti-cancer gene therapy, which is under Phase I clinical trials for treatment of breast cancer; RY103 [NS101], therapeutics antibody for Alzheimer; and RY104, a gene therapy to treat age-related macular degeneration, as well as BIO-101, a HBV gene vaccine, which is in preclinical studies for hepatitis B; RY105, gene therapy to treat liver fibrosis; GB102, for treatment of chronic kidney and coronary artery disease; RY110 which is an iPSC-derived NK cell therapy for solid tumors; RY108, an antifungal drug which is under preclinical study. In addition, the company engages in the research of RY106/RY107, a mRNA-based virus vaccine and gene therapy for anti-virus and rare genetic diseases; and RY109 which is a pDNA-based cancer vaccine for treatment of Ovarian cancer. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Yong-Hwan Yoo28.4 %28.40%
  • Soon-Ok Jeong9.362 %9.36%
  • Jeong-min Yoo7.561 %7.56%
  • Soon-hee Jeong6.359 %6.36%
  • Reyon Pharmaceutical Co., Ltd. ESOA2.69%

Share of the company, as of September 25, 2026

Leadership

  • Soon-Ock Jung — Chairman & CEO, 75
  • Yong-Hwan Yoo — President, CEO & Representative Director, 51
  • Hung-Muk Choi — Executive Director

How much revenue does Reyon Pharmaceutical make?

Reyon Pharmaceutical reported 145.93 billion KRW in revenue for fiscal year 2025, down 1.6% from 148.30 billion KRW in fiscal year 2024. In Q1 2026 revenue was 36.05 billion KRW.

Where does Reyon Pharmaceutical make most of its revenue?

Republic of Korea: 99% of revenue by region in fiscal year 2024, followed by Japan (1%).

What companies are similar to Reyon Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Union Korea Pharm Co., Ltd. (080720.KQ), Hyundai Pharmaceutical Co., Ltd. (004310.KS), Huons Co., Ltd. (243070.KQ), curacle co.,ltd. (365270.KQ).

Has Reyon Pharmaceutical made a profit in recent years?

Net income by fiscal year: FY2021, 5.54 billion KRW; FY2022, 7.43 billion KRW; FY2023, 3.58 billion KRW; FY2024, 4.15 billion KRW; FY2025, a loss of 29.63 billion KRW. It reported a net loss in 1 of these 5 years.

How does Reyon Pharmaceutical's profit margin compare with similar companies?

Net profit margin over the last four reported quarters: Reyon Pharmaceutical, -23.9%; Union Korea Pharm Co., Ltd. (080720.KQ), -95.5%; Hyundai Pharmaceutical Co., Ltd. (004310.KS), 1.3%; Huons Co., Ltd. (243070.KQ), 3.1%; curacle co.,ltd. (365270.KQ), -92.1%; DAE HWA Pharmaceutical Co., Ltd. (067080.KQ), 3.0%; Daewon Pharmaceutical Co., Ltd. (003220.KS), 0.4%.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees461
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
Building A, Mirae Asset Tower, Seoul
Phone
82 2 793 5557
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Reyon Pharmaceutical Co., Ltd. (102460.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/102460.KS

LinkedInLinkedInXXYouTubeYouTube